GREM1 and pancreatic neuroendocrine tumor: The expression of GREM1, a bone morphogenetic protein antagonist, correlates with increased angiogenesis in humans with pancreatic neuroendocrine tumors [119]; whereas, the knock-down of GREM1 in human HK–2 cells increases BMP7 signaling activity [120].